Company Dottikon ES Holding AG

DESN

CH0582581713

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Ratings for Dottikon ES Holding AG

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:11 2024-04-19 am EDT			5-day change	1st Jan Change
230.5 ^CHF	+4.06%		+0.44%	+0.66%

2023	Dottikon ES Posts Lower Fiscal H1 Net Income; Sales Up	MT
2023	Dottikon ES Holding AG Reports Earnings Results for the Half Year Ended September 30, 2023	CI

Dottikon ES Holding AG is a Switzerland-based holding company that specializes in hazardous chemistry and focuses on the exclusive synthesis of fine chemicals for the pharmaceutical and chemical industries. Its product range includes active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, as well as industrial chemicals. Its pharmaceutical products can be found in medications for, among others, heart disease, asthma, high blood pressure and ulcers. Dottikon ES Holding AG's industrial end products include food additives, cosmetics, electro-chemicals, photo-chemicals and agricultural chemicals. The Company also offers distillation plants and thin layer evaporators for the recycling of solvents, as well as high temperature incinerators for the waste treatment of hazardous waste. As of March 31, 2012, the Company had two wholly owned subsidiaries: DOTTIKON EXCLUSIVE SYNTHESIS AG and DOTTIKON ES MANAGEMENT AG. It also held a 33.9%-stake in SYSTAG, System Technik AG.

Number of employees: 678

CHF in Million	2022	Weight	2023	Weight	Delta
Chemicals, Intermediates, and Exclusive Active Pharmaceutical Ingredients 100.0 %	252	100.0 %	319	100.0 %	+26.80%

CHF in Million	2022	Weight	2023	Weight	Delta
Switzerland 100.0 %	252	100.0 %	319	100.0 %	+26.80%

Managers	Title	Age	Since
Markus Blocher CEO	Chief Executive Officer	53	02-12-31
Marlene Born DFI	Director of Finance/CFO	49	04-12-31
Urs Brändli CTO	Chief Tech/Sci/R&D Officer	64	89-12-31
Karin Krause HRO	Human Resources Officer	56	14-12-31
Stephan Kirschbaum PRN	Corporate Officer/Principal	57	08-12-31

Members of the board	Title	Age	Since
Markus Blocher CEO	Chief Executive Officer	53	02-12-31
Alfred Scheidegger BRD	Director/Board Member	67	11-06-30
Bernhard Urwyler BRD	Director/Board Member	66	20-07-02

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	13,999,084	3,901,112 ( 27.87 %)	224,880 ( 1.606 %)	27.87 %

Name	Equities	%	Valuation
Markus Blocher 65.27 %	9,137,397	65.27 %	2 414 M CHF
Peter Grogg 7.000 %	979,936	7.000 %	259 M CHF
Blocher Miriam Baumann 5.107 %	715,000	5.107 %	189 M CHF
UBS Asset Management Switzerland AG 4.182 %	585,420	4.182 %	155 M CHF
DOTTIKON ES HOLDING AG 1.383 %	193,641	1.383 %	51 M CHF
VV Vermögensverwaltung AG 0.9258 %	129,600	0.9258 %	34 M CHF
Union Bancaire Privée, UBP SA 0.5381 %	75,335	0.5381 %	20 M CHF
Reichmuth & Co. 0.1786 %	25,000	0.1786 %	7 M CHF
Pax Asset Management AG 0.1143 %	16,000	0.1143 %	4 M CHF
LBBW Asset Management Investmentgesellschaft mbH 0.0724 %	10,141	0.0724 %	3 M CHF

Name	Equities	%	Valuation
DOTTIKON ES HOLDING AG 1.38%	193,641	1.38%	51,167,491 $

Dottikon ES Holding AG

Hembrunnstrasse 17

5605, Dottikon

+41 56 616 81 11

http://www.dottikon.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

230.5

Average target price

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
DOTTIKON ES HOLDING AG	+0.66%	3.35B
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B

Other Pharmaceuticals